Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1)

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Canuel, Maryssa ^a   Sun, Xiaowei ^a   Asselin, Marie Claude ^a   Paramithiotis, Eustache ^b   Prat, Annik ^a   Seidah, Nabil G ^a  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; PROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL STRAIN HEK293; CELL STRAIN HEPG2; CHO CELL; CONTROLLED STUDY; HUMAN; HUMAN CELL; INTERNALIZATION; LIVER; MELANOMA CELL; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEOMICS;

ANIMALS; CELL LINE, TUMOR; CHOLESTEROL, LDL; CRICETULUS; GENE EXPRESSION REGULATION; HEK293 CELLS; HEP G2 CELLS; HUMANS; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-1; MELANOMA, EXPERIMENTAL; MICE; ORGAN SPECIFICITY; PROPROTEIN CONVERTASES; PROTEIN STRUCTURE, TERTIARY; PROTEOLYSIS; RECEPTORS, LDL; SERINE ENDOPEPTIDASES; SIGNAL TRANSDUCTION;

EID: 84877675332     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064145     Document Type: Article

References (50)

1. Martin SS, Blumenthal RS, Miller M, (2012) LDL cholesterol: the lower the better. Med Clin North Am 96: 13-26.
2. Brown MS, Goldstein JL, (1974) Familial hypercholesterolemia: defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity. Proc Natl Acad Sci U S A 71: 788-792.
3. Maxfield FR, Tabas I, (2005) Role of cholesterol and lipid organization in disease. Nature 438: 612-621.
4. Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, et al. (2003) Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34: 154-156.
5. Marduel M, Ouguerram K, Serre V, Bonnefont-Rousselot D, Marques-Pinheiro A, et al. (2012) Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation. Hum Mutat 34: 83-87.
6. McNutt MC, Lagace TA, Horton JD, (2007) Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells. J Biol Chem 282: 20799-20803.
7. Maxwell KN, Breslow JL, (2004) Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci U S A 101: 7100-7105.
8. Benjannet S, Rhainds D, Essalmani R, Mayne J, Wickham L, et al. (2004) NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem 279: 48865-48875.
9. Park SW, Moon YA, Horton JD, (2004) Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J Biol Chem 279: 50630-50638.
10. Nassoury N, Blasiole DA, Tebon OA, Benjannet S, Hamelin J, et al. (2007) The Cellular Trafficking of the Secretory Proprotein Convertase PCSK9 and Its Dependence on the LDLR. Traffic 8: 718-732.
11. Rashid S, Curtis DE, Garuti R, Anderson NN, Bashmakov Y, et al. (2005) Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci U S A 102: 5374-5379.
12. Zaid A, Roubtsova A, Essalmani R, Marcinkiewicz J, Chamberland A, et al. (2008) Proprotein convertase subtilisin/kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology 48: 646-654.
13. Seidah NG, Prat A, (2012) The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov 11: 367-383.
14. Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, et al. (2003) The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A 100: 928-933.
15. Seidah NG, (2009) PCSK9 as a therapeutic target of dyslipidemia. Expert Opinion on Therapeutic Targets 13: 19-28.
16. Cunningham D, Danley DE, Geoghegan KF, Griffor MC, Hawkins JL, et al. (2007) Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat Struct Mol Biol 14: 413-419.
17. Zhang DW, Lagace TA, Garuti R, Zhao Z, McDonald M, et al. (2007) Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat a of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem 282: 18602-18612.
18. Kwon HJ, Lagace TA, McNutt MC, Horton JD, Deisenhofer J, (2008) Molecular basis for LDL receptor recognition by PCSK9. Proc Natl Acad Sci U S A 105: 1820-1825.
19. Zhang DW, Garuti R, Tang WJ, Cohen JC, Hobbs HH, (2008) Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor. Proc Natl Acad Sci U S A 105: 13045-13050.
20. Yamamoto T, Lu C, Ryan RO, (2011) A two-step binding model of PCSK9 interaction with the low density lipoprotein receptor. J Biol Chem 286: 5464-5470.
21. Poirier S, Mayer G, Poupon V, McPherson PS, Desjardins R, et al. (2009) Dissection of the endogenous cellular pathways of PCSK9-induced LDLR degradation: Evidence for an intracellular route. J Biol Chem 284: 28856-28864.
22. Luna Saavedra YG, Day R, Seidah NG (2012) The M2 module of the Cys-His-rich domain (CHRD) of PCSK9 is needed for the extracellular low density lipoprotein receptor (LDLR) degradation pathway. J Biol Chem.
23. Lagace TA, Curtis DE, Garuti R, McNutt MC, Park SW, et al. (2006) Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice. J Clin Invest 116: 2995-3005.
24. Garcia CK, Wilund K, Arca M, Zuliani G, Fellin R, et al. (2001) Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science 292: 1394-1398.
25. He G, Gupta S, Yi M, Michaely P, Hobbs HH, et al. (2002) ARH is a modular adaptor protein that interacts with the LDL receptor, clathrin, and AP-2. J Biol Chem 277: 44044-44049.
26. Davis CG, Lehrman MA, Russell DW, Anderson RG, Brown MS, et al. (1986) The J.D. mutation in familial hypercholesterolemia: amino acid substitution in cytoplasmic domain impedes internalization of LDL receptors. Cell 45: 15-24.
27. Timms KM, Wagner S, Samuels ME, Forbey K, Goldfine H, et al. (2004) A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum Genet 114: 349-353.
28. Strom TB, Holla OL, Tveten K, Cameron J, Berge KE, et al. (2010) Disrupted recycling of the low density lipoprotein receptor by PCSK9 is not mediated by residues of the cytoplasmic domain. Mol Genet Metab 101: 76-80.
29. Sun X, Essalmani R, Day R, Khatib AM, Seidah NG, et al. (2012) Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver. Neoplasia 14: 1122-1131.
30. Scamuffa N, Calvo F, Chretien M, Seidah NG, Khatib AM, (2006) Proprotein convertases: lessons from knockouts. FASEB J 20: 1954-1963.
31. Benjannet S, Saavedra YG, Hamelin J, Asselin MC, Essalmani R, et al. (2010) Effects of the prosegment and pH on the activity of PCSK9: evidence for additional processing events. J Biol Chem 285: 40965-40978.
32. Benjannet S, Hamelin J, Chretien M, Seidah NG, (2012) Loss- and Gain-of-function PCSK9 Variants: Clevage specificity, dominant negative effects, and low density lipoprotein receptor (LDLR) degradation. J Biol Chem 287: 33745-33755.
33. Benjannet S, Rhainds D, Hamelin J, Nassoury N, Seidah NG, (2006) The proprotein convertase PCSK9 is inactivated by furin and/or PC5/6A: Functional consequences of natural mutations and post-translational modifications. J Biol Chem 281: 30561-30572.
34. Poirier S, Mayer G, Benjannet S, Bergeron E, Marcinkiewicz J, et al. (2008) The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem 283: 2363-2372.
35. Dubuc G, Chamberland A, Wassef H, Davignon J, Seidah NG, et al. (2004) Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 24: 1454-1459.
36. Boucher P, Herz J, (2011) Signaling through LRP1: Protection from atherosclerosis and beyond. Biochem Pharmacol 81: 1-5.
37. Franchini M, Montagnana M, (2011) Low-density lipoprotein receptor-related protein 1: new functions for an old molecule. Clin Chem Lab Med 49: 967-970.
38. Lillis AP, Van Duyn LB, Murphy-Ullrich JE, Strickland DK, (2008) LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol Rev 88: 887-918.
39. Jang A, Hill RP, (1991) Drug sensitivity and metastatic ability in B16 melanoma cells. Clin Exp Metastasis 9: 393-402.
40. May P, Woldt E, Matz RL, Boucher P, (2007) The LDL receptor-related protein (LRP) family: an old family of proteins with new physiological functions. Ann Med 39: 219-228.
41. FitzGerald DJ, Fryling CM, Zdanovsky A, Saelinger CB, Kounnas M, et al. (1995) Pseudomonas exotoxin-mediated selection yields cells with altered expression of low-density lipoprotein receptor-related protein. J Cell Biol 129: 1533-1541.
42. Roubtsova A, Munkonda MN, Awan Z, Marcinkiewicz J, Chamberland A, et al. (2011) Circulating Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Regulates VLDLR Protein and Triglyceride Accumulation in Visceral Adipose Tissue. Arterioscler Thromb Vasc Biol 31: 785-791.
43. Krieger M, Herz J, (1994) Structures and functions of multiligand lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related protein (LRP). Annu Rev Biochem 63: 601-637.
44. Willnow TE, (1999) The low-density lipoprotein receptor gene family: multiple roles in lipid metabolism. J Mol Med (Berl) 77: 306-315.
45. Kysenius K, Muggalla P, Matlik K, Arumae U, Huttunen HJ, (2012) PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling. Cell Mol Life Sci 69: 1903-1916.
46. Mayer G, Poirier S, Seidah NG, (2008) Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels. J Biol Chem 283: 31791-31801.
47. Seidah NG, Poirier S, Denis M, Parker R, Miao B, et al. (2012) Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation. PLoS ONE 7: e41865.
48. Jehle AW, Gardai SJ, Li S, Linsel-Nitschke P, Morimoto K, et al. (2006) ATP-binding cassette transporter A7 enhances phagocytosis of apoptotic cells and associated ERK signaling in macrophages. J Cell Biol 174: 547-556.
49. Stein EA, Gipe D, Bergeron J, Gaudet D, Weiss R, et al. (2012) Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 380: 29-36.
50. Langlois B, Emonard H, Martiny L, Dedieu S, (2009) Multiple involvements of LRP-1 receptor in tumor progression. Pathol Biol (Paris) 57: 548-554.